209 related articles for article (PubMed ID: 23493192)
1. Biomarker-driven patient selection for early clinical trials.
Dienstmann R; Rodon J; Tabernero J
Curr Opin Oncol; 2013 May; 25(3):305-12. PubMed ID: 23493192
[TBL] [Abstract][Full Text] [Related]
2. Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies.
Dienstmann R; Rodon J; Tabernero J
Am Soc Clin Oncol Educ Book; 2012; ():168-72. PubMed ID: 24451729
[TBL] [Abstract][Full Text] [Related]
3. Drug development for cancer chemoprevention: focus on molecular targets.
Johnson KA; Brown PH
Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
[TBL] [Abstract][Full Text] [Related]
4. Genomic medicine frontier in human solid tumors: prospects and challenges.
Dienstmann R; Rodon J; Barretina J; Tabernero J
J Clin Oncol; 2013 May; 31(15):1874-84. PubMed ID: 23589551
[TBL] [Abstract][Full Text] [Related]
5. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
6. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
Garcia VM; Cassier PA; de Bono J
Cancer Discov; 2011 Aug; 1(3):207-12. PubMed ID: 22586572
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials in drug development: a minimalistic approach.
Verweij J
Curr Opin Oncol; 2012 May; 24(3):332-7. PubMed ID: 22343389
[TBL] [Abstract][Full Text] [Related]
8. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
9. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
10. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
11. Early oncology clinical trial design in the era of molecular-targeted agents.
Brunetto AT; Kristeleit RS; de Bono JS
Future Oncol; 2010 Aug; 6(8):1339-52. PubMed ID: 20799878
[TBL] [Abstract][Full Text] [Related]
12. Personalizing prostate cancer therapy: the way forward.
Cetnar JP; Beer TM
Drug Discov Today; 2014 Sep; 19(9):1483-7. PubMed ID: 25046532
[TBL] [Abstract][Full Text] [Related]
13. From darkness to light with biomarkers in early clinical trials of cancer drugs.
Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
[TBL] [Abstract][Full Text] [Related]
14. Personalized-medicine trials on the rise.
Benowitz S
J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
[No Abstract] [Full Text] [Related]
15. Personalized oncology: genomic screening in phase 1.
Tuxen IV; Jønson L; Santoni-Rugiu E; Hasselby JP; Nielsen FC; Lassen U
APMIS; 2014 Aug; 122(8):723-33. PubMed ID: 25046202
[TBL] [Abstract][Full Text] [Related]
16. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.
Hollebecque A; Massard C; Soria JC
Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials and biomarker development with molecularly targeted agents and radiotherapy.
Dhani N; Siu LL
Cancer Metastasis Rev; 2008 Sep; 27(3):339-49. PubMed ID: 18379730
[TBL] [Abstract][Full Text] [Related]
18. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
19. Genomic biomarkers for patient selection and stratification: the cancer paradigm.
Moschos SA
Bioanalysis; 2012 Oct; 4(20):2499-511. PubMed ID: 23157358
[TBL] [Abstract][Full Text] [Related]
20. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
